2023
An international research agenda for clozapine-resistant schizophrenia
Luykx J, Gonzalez-Diaz J, Guu T, van der Horst M, van Dellen E, Boks M, Guloksuz S, DeLisi L, Sommer I, Cummins R, Shiers D, Lee J, Every-Palmer S, Mhalla A, Chadly Z, Chan S, Cotes R, Takahashi S, Benros M, Wagner E, Correll C, Hasan A, Siskind D, Endres D, MacCabe J, Tiihonen J. An international research agenda for clozapine-resistant schizophrenia. The Lancet Psychiatry 2023, 10: 644-652. PMID: 37329895, DOI: 10.1016/s2215-0366(23)00109-8.Peer-Reviewed Original ResearchConceptsClozapine-resistant schizophreniaQuality of lifeTreatment optionsTreatment-resistant symptomsThird of patientsNew treatment optionsHealth care providersMiddle-income countriesFunctional outcomeInterventional studyUnmet needEpidemiological researchTranslational approachDiagnostic testsPatientsSchizophreniaHealth policyEarly detectionOptionsSymptomsDiagnosisTrials
2017
A critique of the “ultra‐high risk” and “transition” paradigm
van Os J, Guloksuz S. A critique of the “ultra‐high risk” and “transition” paradigm. World Psychiatry 2017, 16: 200-206. PMID: 28498576, PMCID: PMC5428198, DOI: 10.1002/wps.20423.Peer-Reviewed Original ResearchClinical high riskUltra-high riskCommon mental disordersMental disordersPsychotic experiencesCHR researchHigh-risk approachMental health problemsPublic health perspectiveFalse-positive findingsTransdiagnostic expressionClinical picturePoor outcomePoor prognosisFunctional outcomeBaseline differencesHigh riskOmega-3Health problemsPositive findingsEpidemiological researchDiagnostic shiftUHR sampleYoung individualsHealth perspective